ArticleCancer immunology, immunotherapy : CII2015

Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.

Hiromitsu Araki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.